{"id":"placebo-avastin-platinum-based-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Bleeding/thromboembolic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Platinum agents (e.g., cisplatin, carboplatin) create DNA crosslinks to kill rapidly dividing cancer cells. Bevacizumab is a monoclonal antibody targeting VEGF (vascular endothelial growth factor), which inhibits angiogenesis and starves tumors of blood supply. The placebo arm allows comparison of the active combination's efficacy in this Phase 3 trial.","oneSentence":"This combination uses platinum-based chemotherapy to damage cancer cell DNA while bevacizumab (Avastin) blocks tumor blood vessel formation, with placebo as a control arm.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:37.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer (likely, given ARCAGY/GINECO GROUP focus on gynecologic malignancies)"}]},"trialDetails":[{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT03602859","phase":"PHASE3","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2018-10-11","conditions":"Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","enrollment":1400},{"nctId":"NCT04982237","phase":"PHASE3","title":"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-08-27","conditions":"Cervical Cancer","enrollment":445},{"nctId":"NCT05179239","phase":"PHASE3","title":"A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-02-26","conditions":"Cervical Cancer","enrollment":31},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT03737643","phase":"PHASE3","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-04","conditions":"Advanced Ovarian Cancer","enrollment":1407},{"nctId":"NCT06755515","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-09-26","conditions":"Cervical Cancer","enrollment":510},{"nctId":"NCT06349044","phase":"NA","title":"A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-03-20","conditions":"Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma","enrollment":120},{"nctId":"NCT04677504","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Biliary Tract Cancer","enrollment":162},{"nctId":"NCT00942331","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-15","conditions":"Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma","enrollment":506},{"nctId":"NCT05798819","phase":"PHASE3","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2023-05-01","conditions":"Persistent, Recurrent, or Metastatic Cervical Cancer","enrollment":424},{"nctId":"NCT05715840","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-01-31","conditions":"Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","enrollment":368},{"nctId":"NCT05446883","phase":"PHASE3","title":"QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-09-23","conditions":"METASTATIC CERVICAL CANCER","enrollment":498},{"nctId":"NCT05132413","phase":"PHASE3","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer","enrollment":561},{"nctId":"NCT03912415","phase":"PHASE3","title":"Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)","status":"UNKNOWN","sponsor":"Biocad","startDate":"2019-10-01","conditions":"Cervical Cancer","enrollment":316},{"nctId":"NCT00548548","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-09","conditions":"Adenocarcinoma","enrollment":774},{"nctId":"NCT00887822","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Gastric Cancer","enrollment":202},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00806923","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-02","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":1044},{"nctId":"NCT01496742","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-04","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":259},{"nctId":"NCT00027703","phase":"PHASE2","title":"Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10","conditions":"Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo + avastin + platinum-based chemotherapy","genericName":"placebo + avastin + platinum-based chemotherapy","companyName":"ARCAGY/ GINECO GROUP","companyId":"arcagy-gineco-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses platinum-based chemotherapy to damage cancer cell DNA while bevacizumab (Avastin) blocks tumor blood vessel formation, with placebo as a control arm. Used for Ovarian cancer (likely, given ARCAGY/GINECO GROUP focus on gynecologic malignancies).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}